And SGLT2 inhibitors "should only be used with great caution, extensive counseling, and close monitoring in the setting of type 1 diabetes," they caution.
And because the beneficial effects of SGLT2 inhibitors in the prevention of cardiovascular and renal disease will probably increase their uptake in the coming years, "Physicians should be aware of DKA as a potential adverse effect," Douros and colleagues write. Analysis "Generally Confirms What Has...
and EvaluationDrug-Related Side Effects and Adverse ReactionsOverview of:Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis.Ann Intern Med2020;173:417-25.doi:10.1136/dtb.2021.000007...
Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported phenomenon. Not much is known about the burden of EuDKA in patients on SGLT2i or the associated factors. This retrosp...
DKA has also been reported in people with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitors.[7] DKA also occurs in pregnant women, either with preexisting diabetes or with diabetes diagnosed during pregnancy. Physiologic changes unique to pregnancy provide a background...
Euglycemic DKA is DKA with glucose < 250 mg/dL, which occurs in up to 10% of patients with DKA.[2,3,44]Causes include SGLT2 inhibitors, decreased hepatic glucose production (starvation, pregnancy), and partial treatment with insulin before the patient presents to the ED. If the anion gap...
Food and Drug Administration (FDA) has not approved SGLT2 inhibitors as adjunctive therapy in type 1 diabetes over concerns of DKA. To address these concerns, vTV ran this mechanistic study to show that TTP399, a liver-selective glucokinase activator, doesn’t increase ketones. “This ...
(1) Most patients with DKA while on SGLT 2 inhibitor have a precipitating event like dehydration, infection, surgery or change in insulin dose. We propose that strict carbohydrate diet and continuation of SGLT2 inhibitors before bariatric surgery resulted in EDKA. It led to complications peri-...
Introduction Tirzepatide has side effects of diarrhea, nausea, vomiting, and loss of appetite(2). SGLT-2 inhibitors may cause Euglycemic Diabetic ketoacidosis(EDKA) by inducing carbohydrate starvation and volume depletion(1). Clinical Case A 72-year-old male with a past medical history of T2DM...
480: COMPARISON OF TREATMENT OF KETOACIDOSIS ASSOCIATED WITH SGLT-2 INHIBITORS AND USUAL DKAKeywords:perspective;chief resident;emergency medical services (EMS)doi:10.1097/01.ccm.0000509158.18009.37Padmaraj DuvvuriJeffery SprayMarcia BrackbillAbhijit Duggal...